These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28732774)

  • 1. Vaginal dysbiosis and pre-exposure prophylaxis efficacy.
    van de Wijgert J; McCormack S
    Lancet HIV; 2017 Oct; 4(10):e427-e429. PubMed ID: 28732774
    [No Abstract]   [Full Text] [Related]  

  • 2. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
    Velloza J; Heffron R
    Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The global health impact of vaginal dysbiosis.
    van de Wijgert JHHM; Jespers V
    Res Microbiol; 2017; 168(9-10):859-864. PubMed ID: 28257809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The microbiome and HIV prevention strategies in women.
    Abdool Karim SS; Passmore JS; Baxter C
    Curr Opin HIV AIDS; 2018 Jan; 13(1):81-87. PubMed ID: 29059077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis.
    Koester KA; Grant RM
    Clin Infect Dis; 2015 Nov; 61(10):1604-5. PubMed ID: 26334051
    [No Abstract]   [Full Text] [Related]  

  • 6. [PrEP (pre-exposure prophylaxis) for women: what are the benefits of the vaginal ring?].
    Oberhofer E
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():11. PubMed ID: 27259891
    [No Abstract]   [Full Text] [Related]  

  • 7. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
    Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK
    J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
    Dobard CW; Sharma S; Cong ME; West R; Makarova N; Holder A; Pau CP; Hanson DL; Novembre FJ; Garcia-Lerma JG; Heneine W
    Retrovirology; 2015 Aug; 12():69. PubMed ID: 26253002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial.
    Balzer L; Staples P; Onnela JP; DeGruttola V
    Clin Trials; 2017 Apr; 14(2):201-210. PubMed ID: 28124579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HIV pre-exposure prophylaxis in women].
    Haberl A
    MMW Fortschr Med; 2017 Jun; 159(Suppl 2):42-44. PubMed ID: 28597264
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaginal Microbiota.
    Mendling W
    Adv Exp Med Biol; 2016; 902():83-93. PubMed ID: 27161352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CROI 2018: Epidemic Trends and Advances in HIV Prevention.
    Buchbinder SP; Liu AY
    Top Antivir Med; 2018 May; 26(1):1-16. PubMed ID: 29727292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is pericoital or peri-insemination preexposure prophylaxis effective human immunodeficiency prevention for vaginal exposures?
    Seidman DL; Weber S; Grant RM
    Am J Obstet Gynecol; 2017 Aug; 217(2):230-231. PubMed ID: 28479285
    [No Abstract]   [Full Text] [Related]  

  • 14. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.
    Tan DHS; Hull MW; Yoong D; Tremblay C; O'Byrne P; Thomas R; Kille J; Baril JG; Cox J; Giguere P; Harris M; Hughes C; MacPherson P; O'Donnell S; Reimer J; Singh A; Barrett L; Bogoch I; Jollimore J; Lambert G; Lebouche B; Metz G; Rogers T; Shafran S;
    CMAJ; 2017 Nov; 189(47):E1448-E1458. PubMed ID: 29180384
    [No Abstract]   [Full Text] [Related]  

  • 15. The FACTS about women and pre-exposure prophylaxis.
    Seidman D; Weber S; Aaron E; Cohan D; Grant R
    Lancet HIV; 2015 Jun; 2(6):e228. PubMed ID: 26423194
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV pre-exposure prophylaxis (PrEP): Is it time to rethink HIV prevention in travelers?
    Hampel B; Reinacher M; Fehr JS
    Travel Med Infect Dis; 2018; 25():6-7. PubMed ID: 29929002
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.
    Wahl A; Ho PT; Denton PW; Garrett KL; Hudgens MG; Swartz G; O'Neill C; Veronese F; Kashuba AD; Garcia JV
    Sci Rep; 2017 Feb; 7():41098. PubMed ID: 28145472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polarised press reporting about HIV prevention: Social representations of pre-exposure prophylaxis in the UK press.
    Jaspal R; Nerlich B
    Health (London); 2017 Sep; 21(5):478-497. PubMed ID: 27216725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INFECTIOUS DISEASE. Vaginal microbiome affects HIV risk.
    Cohen J
    Science; 2016 Jul; 353(6297):331. PubMed ID: 27463647
    [No Abstract]   [Full Text] [Related]  

  • 20. Pre-exposure prophylaxis for the prevention of HIV infection: a new prevention paradigm?
    Sánchez-Rubio Ferrández J; Martínez Sesmero JM
    Farm Hosp; 2016 May; 40(3):219-24. PubMed ID: 27145390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.